Retrospective Analysis of Efficacy and Toxicity of Stereotactic Body Radiotherapy and Surgical Resection of Adrenal Metastases from Solid Tumors

被引:0
|
作者
Lutscher, Jamie [1 ]
Gelpke, Hans [2 ]
Zehnder, Adrian [2 ]
Mauti, Laetitia [3 ]
Padevit, Christian [4 ]
John, Hubert [4 ]
Batifi, Nidar [1 ]
Zwahlen, Daniel Rudolf [1 ]
Forster, Robert [1 ,5 ]
Schroder, Christina [1 ]
机构
[1] Cantonal Hosp Winterthur, Dept Radiat Oncol, CH-8401 Winterthur, Switzerland
[2] Cantonal Hosp Winterthur, Dept Visceral & Thorac Surg, CH-8401 Winterthur, Switzerland
[3] Cantonal Hosp Winterthur, Dept Med Oncol, CH-8401 Winterthur, Switzerland
[4] Cantonal Hosp Winterthur, Dept Urol, CH-8401 Winterthur, Switzerland
[5] Univ Bern, Bern Univ Hosp, Dept Radiat Oncol, Inselspital, CH-3010 Bern, Switzerland
关键词
adrenalectomy; stereotactic body radiation therapy; adrenal metastases; local control; progression free survival; overall survival; complication rate; RADIATION-THERAPY; OUTCOMES; GLAND; SURVIVAL; PATTERNS; SURGERY;
D O I
10.3390/cancers16152655
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The adrenal glands represent a frequent localization area for metastases of various primary tumors. The standard of care for treating adrenal metastases is currently surgical resection, but radiotherapy is becoming a feasible and well-tolerated treatment alternative. However, the literature shows contradictory results regarding the optimal local treatment for adrenal metastases. This study analyzed oncological outcomes (local control, progression free survival, and overall survival) and complication rates after stereotactic body radiotherapy or surgical resection of adrenal metastases to further asses the benefits of stereotactic body radiotherapy. To our knowledge, this analysis is the first direct comparison of stereotactic body radiotherapy and adrenalectomy for adrenal metastases.Abstract Background: This single-center retrospective study aimed to evaluate the efficacy and toxicity profiles of stereotactic body radiotherapy (SBRT) and surgical resection in patients with adrenal metastases originating from solid tumors. Methods/Materials: Patients with advanced tumor conditions or comorbidities typically received SBRT, whereas those considered physically fit underwent standard surgical treatment. Endpoints included local control (LC), progression free survival (PFS), overall survival (OS), and complication rates (CR). Results: 41 patients with 48 adrenal metastases were included, with 27 (65.9%) patients receiving SBRT and 14 (34.1%) patients undergoing adrenalectomy. One- and two-year LC values were 100% for both periods after adrenalectomy, and 70.0% and 52.5% after SBRT (p = 0.001). PFS showed values of 40.2% and 32.1% at one and two years after adrenalectomy and of 10.6% for both periods after SBRT (p = 0.223). OS was 83.3% both one and two years after surgery and 67.0% and 40.2% after SBRT (p = 0.031). There was no statistically significant difference between the two groups regarding acute complications (p = 0.123). Conclusion: Despite potential confounders, adrenalectomy exhibited statistically significant superior LC and OS compared to SBRT in managing adrenal metastases, while both treatment methods displayed acceptable toxicity profiles. However, patient selection bias must be taken into account when directly comparing the two therapy modalities. Nevertheless, the study provides new and important results for the scientific and medical communities regarding oncological outcomes after SBRT or surgical resection of adrenal metastases.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Stereotactic body radiotherapy for adrenal metastases of oligometastatic or oligoprogressive tumors
    Koenig, L.
    Haefner, M. F.
    Katayama, S.
    Koerber, S. A.
    Tonndorf-Martini, E.
    Bernhardt, D.
    Von Nettelbladt, B.
    Weykamp, F.
    Hoegen, P.
    Klueter, S.
    Susko, M. S.
    Debus, J.
    Hoerner-Rieber, J.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S563 - S563
  • [2] Stereotactic Body Radiotherapy for the Treatment of Adrenal Metastases: A Retrospective Review
    Torok, Jordan
    Wegner, Rodney
    Burton, Steven
    Heron, Dwight
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 204 - 204
  • [3] The efficacy and outcomes of stereotactic body radiotherapy in adrenal gland metastases
    Kekilli, Esra
    Demirkasimoglu, Taciser
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S47 - S51
  • [4] STEREOTACTIC BODY RADIOTHERAPY FOR TREATMENT OF ADRENAL METASTASES
    Chawla, Sheema
    Chen, Yuhchyau
    Katz, Alan W.
    Muhs, Ann G.
    Philip, Abraham
    Okunieff, Paul
    Milano, Michael T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01): : 71 - 75
  • [5] Stereotactic Body Radiotherapy in the Treatment of Adrenal Metastases
    Ahmed, Kamran A.
    Barney, Brandon M.
    Macdonald, O. Kenneth
    Miller, Robert C.
    Garces, Yolanda I.
    Laack, Nadia N.
    Haddock, Michael G.
    Foote, Robert L.
    Olivier, Kenneth R.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (05): : 509 - 513
  • [6] Stereotactic ablative Radiotherapy (SABR) for Adrenal Metastases: high Efficacy with low Toxicity
    Koos, V
    Kretschmer, M.
    Dahle, J.
    Sabatino, M.
    Feine, D.
    Wuerschmidt, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S43 - S44
  • [7] Stereotactic body radiotherapy for adrenal metastases from lung cancer
    Guiou, Michael
    Mayr, Nina A.
    Kim, Edward Y.
    Williams, Terence
    Lo, Simon S.
    JOURNAL OF RADIATION ONCOLOGY, 2012, 1 (02) : 155 - 163
  • [8] Long-Term Outcome and Toxicity of Stereotactic Ablative Body Radiotherapy (SABR) for Liver Metastases From Solid Tumors
    Lu, Yi
    Tang, Chad
    Liao, Zhongxing
    Jeter, Melenda
    Hahn, Stephen
    Das, Prajnan
    Koay, Eugene
    Herman, Joseph
    Quynh-Nhu Nguyen
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E14 - E14
  • [9] Toxicity and Efficacy of Stereotactic Body Radiotherapy plus Nivolumab with Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors
    Foster, C. C.
    Fleming, G.
    Karrison, T. G.
    Liao, C. Y.
    Desai, A. V.
    Moroney, J. W.
    Ratain, M. J.
    Nanda, R.
    Polite, B. N.
    Hahn, O.
    O'Donnell, P. H.
    Undevia, S. D.
    Vokes, E. E.
    Kindler, H.
    Szmulewitz, R.
    Hseu, R.
    Janisch, L.
    Pitroda, S. P.
    Luke, J. J.
    Chmura, S. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S88 - S88
  • [10] Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease
    Rosenbrock, Johannes
    Lieser, Annabell
    Ostermann-Myrau, Julia
    Judge, Michael
    Linde, Philipp
    Claus, Karina
    Marnitz, Simone
    Kocher, Martin
    Baues, Christian
    Celik, Eren
    ANTICANCER RESEARCH, 2023, 43 (09) : 4125 - 4131